Stockreport

Liquidia: Yutrepia's Attributes In Focus, But Binary Risk Shouldn't Be Ignored [Seeking Alpha]

Liquidia Corporation  (LQDA) 
Last liquidia corporation earnings: 3/11 07:00 am Check Earnings Report
PDF LQDA's Yutrepia demonstrates superior tolerability, higher achievable dosing, and rapid titration versus Tyvaso, driving robust commercial uptake and market share gains [Read more]